Amber Therapeutics raises $100M Series A to support neuromod tech

Amber Therapeutics announced today that it closed a Series A financing totaling $100 million to support its neuromodulation therapy.
London-based Amber develops adaptive neuromodulation technology to treat mixed urinary incontinence (MUI). Amber-UI, a fully implantable system, targets the pudendal nerve through a novel, minimally invasive surgical procedure. The company labeled it the first fully implantable adaptive neuromodulation therapy in development for women with MUI.